1stOncology™: Cancer Intelligence Service – Page 258 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Moderna to Present at Upcoming Piper Sandler’s 37th Annual Healthcare Conference on December 2, 2025

On November 18, 2025 Moderna, Inc. (Nasdaq:MRNA), reported its participation in the following upcoming investor conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Piper Sandler’s 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET

A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.

(Press release, Moderna Therapeutics, NOV 18, 2025, https://feeds.issuerdirect.com/news-release.html?newsid=8786998755631678&symbol=MRNA [SID1234660060])

Lilly to participate in Citi’s 2025 Global Healthcare Conference

On November 18, 2025 Eli Lilly and Company (NYSE:LLY) reported it will participate in the Citi’s 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

(Press release, Eli Lilly, NOV 18, 2025, View Source [SID1234660059])

Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

On November 18, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA.

The DDR Inhibitors Summit is recognized as a premier global forum uniting translational scientists, clinicians, and biotechnology innovators working to advance next-generation DDR-targeted cancer therapies. The 2026 program will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, with a strong focus on translational strategies to accelerate clinical impact.

Prof. Daugaard will deliver a featured presentation titled:

"Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics"

His session will highlight Rakovina’s pivot to an AI-enabled drug discovery model and showcase studies of AI-designed DDR programs progressing through preclinical lead selection and toward development.

In addition to his presentation, Prof. Daugaard will participate in a fireside chat entitled "Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures" and a panel discussion on "Uniting Founders and Funders to Align Scientific Vision with Investment Strategy." In these sessions, he will join a distinguished group of global oncology leaders to discuss evolving DDR biology, resistance mechanisms, and next-generation clinical strategies.

"The DDR field is undergoing a profound shift, driven by new discoveries in DNA damage response biology, smarter combination strategies, and the integration of AI into early discovery," said Prof. Daugaard. "We are excited to contribute to the scientific dialogue shaping the future of targeted oncology, and to share how AI can accelerate the development of precisely engineered DDR therapeutics designed for clinical impact."

As a co-founder of Rakovina and an Associate Professor at the University of British Columbia, Prof. Daugaard brings deep expertise in cancer biology and therapeutic resistance, with a research focus on uncovering vulnerabilities in tumor survival pathways and advancing them toward targeted drug discovery. His participation in the 9th DDR Inhibitors Summit reinforces the momentum behind Rakovina’s AI-accelerated DDR pipeline and highlights the Company’s role within a collaborative global effort to deliver new therapeutic options for patients with difficult-to-treat cancers.

(Press release, Rakovina Therapeutics, NOV 18, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-president-cso-to-present-and-join-expert-panel-at-the-9th-annual-ddr-inhibitors-summit [SID1234660058])

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

On November 18, 2025 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company’s investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs).

The live event and accompanying slides can be accessed by visiting View Source, or via the Events and Presentations section of the Company’s website: View Source A replay of the webcast will be archived for a limited time following the event.

About TARA-002 in LMs

TARA-002 is an investigational, genetically distinct strain of streptococcus pyogenes that is inactivated while retaining its immune-stimulating properties. It was developed from the same master cell banks as OK-432, which was originally granted marketing approval by the Japanese Ministry of Health for the treatment of LMs and has been the standard of care in Japan for 30 years. In addition, OK-432 was studied in a large Phase 2 trial in LMs in over 500 patients with significant clinical success. TARA-002 has been granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration for the treatment of LMs.

About Lymphatic Malformations

Lymphatic malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of three years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels and lymphatics; recurrent infection; and cosmetic and other functional disabilities.

(Press release, Protara Therapeutics, NOV 18, 2025, https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-host-conference-call-and-webcast-review-0 [SID1234660057])

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

On November 18, 2025 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema.

In connection with the proposed offering, Olema expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock Olema is offering plus the shares of common stock underlying the pre-funded warrants. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

TD Cowen is acting as book-running manager for the proposed offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the "SEC") on January 6, 2025 and declared effective on January 15, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at View Source Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Olema Oncology, NOV 18, 2025, View Source [SID1234660056])